BiologicalDrug
Sargramostim clinical trials
Also written DRG-0012 and BAY86-5326.
- studies test it
- 158
- open now
- 3
- in phase 3
- 19
- first study started
- 1993
Keep track of what changes. Save the sargramostim studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- sargramostim
- 133
- Leukine
- 62
- GM-CSF
- 35
- Prokine
- 31
Development codes
- DRG-0012
- 15
Combined with it in one product
Studies by the year they started
154 studies that test it; most in 2000 (13)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1995 | 3 |
| 1996 | 3 |
| 1997 | 4 |
| 1998 | 4 |
| 1999 | 7 |
| 2000 | 13 |
| 2001 | 10 |
| 2002 | 7 |
| 2003 | 9 |
| 2004 | 13 |
| 2005 | 6 |
| 2006 | 11 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 3 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 51
- Phase 2
- 98
- Phase 3
- 19
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 132
National Cancer Institute (NCI) (22) · Genzyme, a Sanofi Company (8) · Children's Oncology Group (6) · University of Nebraska (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Roswell Park Cancer Institute (5) · University of Washington (4) · Partner Therapeutics, Inc. (4)
Often tested with
Tested in the same studies.
Cyclophosphamide (9) · Rituximab (8) · Etoposide (8) · Aldesleukin (7) · Dinutuximab (6) · Doxorubicin (6) · Filgrastim (6) · Isotretinoin (4)
Studies
Open first, then newest update. How each study uses sargramostim is read from its arms, and is right about nine times in ten.
Testing it · 158
- GM-CSF With Post-Transplant CyclophosphamideRecruitingPhase 2Northside Hospital, Inc.NCT04237623Written as Sargramostim
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06528496Written as Sargramostim
- Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's DiseaseRecruitingPhase 2University of Colorado, DenverNCT04902703Written as Sargramostim
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00669734Written as Sargramostim
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01134614Written as Sargramostim
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT02339571Written as Sargramostim
- Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedPhase 3National Cancer Institute (NCI)NCT01989572Written as Sargramostim
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT01041638Written as Sargramostim
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedPhase 2National Cancer Institute (NCI)NCT03786783Written as Sargramostim
- GM-CSF to Decrease ICU Acquired InfectionsCompletedPhase 3Hospices Civils de LyonNCT02361528Written as Sargramostim: Leukine (Genzyme USA)
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT00026312Written as Sargramostim
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT03879694Written as Sargramostim
- Biomarker Assessments of Leukine During Treatment of Parkinson's DiseaseCompletedPhase 1University of NebraskaNCT03790670Written as sargramostim
- Biomarker Validation Following Sargramostim Treatment in Parkinson's DiseaseCompletedPhase 1University of NebraskaNCT05677633Written as Sargramostim
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingPhase 2Children's Oncology GroupNCT04385277Written as Sargramostim
- Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedPhase 1University of WashingtonNCT00436254Written as sargramostim
- Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down SyndromeWithdrawnPhase 2University of Colorado, DenverNCT05482334Written as Sargramostim for Injection
- A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate CancerCompletedPhase 1/2Ultimovacs ASANCT01784913Written as UV1 synthetic peptide vaccine and GM-CSF
- A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.CompletedPhase 1/2Ultimovacs ASANCT01789099Written as UV1 synthetic peptide vaccine and GM-CSF
- A Phase II/III Study of SargramostimCompletedPhase 2/3NobelpharmaNCT04642950Written as Sargramostim
See all 158 studies that test sargramostim →
Given in every arm · 72 — sargramostim is usual care beside what is tested
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as Sargramostim
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT06202066Written as Sargramostim
- Testing the SurVaxM Vaccine for Lung Cancer PreventionNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07169617Written as Sargramostim
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Sargramostim
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingPhase 1/2Mayo ClinicNCT05269381Written as Sargramostim
- A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaRecruitingPhase 2St. Jude Children's Research HospitalNCT07085338Written as Sargramostim
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT07078604Written as Sargramostim
- A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung CancerRecruitingPhase 2University of WashingtonNCT05242965Written as Sargramostim
- Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaRecruitingPhase 1Steven DuBois, MDNCT07027748Written as Sargramostim granulocyte-macrophage colony stimulating factor
- Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung CancerRecruitingPhase 2Vestre Viken Hospital TrustNCT05344209Written as Sagramostim
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Roswell Park Cancer InstituteNCT02455557Written as Sargramostim
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingPhase 1/2Nationwide Children's HospitalNCT04211675Written as Sargramostim
- STEMVAC in Patients With Early Stage Triple Negative Breast CancerActive, not recruitingPhase 2University of WashingtonNCT05455658Written as Sargramostim
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerActive, not recruitingPhase 2Aston Sci. Inc.NCT05771584Written as rhuGM-CSF
- Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerActive, not recruitingPhase 2Academic and Community Cancer Research UnitedNCT03012100Written as Sargramostim
- A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage AdenocarcinomaSuspendedPhase 1/2University of California, DavisNCT05101356Written as Sargramostim
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingPhase 1Roswell Park Cancer InstituteNCT02334865Written as Sargramostim
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingPhase 2Children's Oncology GroupNCT03794349Written as Sargramostim
- Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT04040231Written as Sargramostim
- MIBG With Dinutuximab +/- VorinostatCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT03332667Written as Sargramostim
Showing 20 of 72.
As the comparator · 2 — what is tested is compared with sargramostim
- Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT02636582Written as Sargramostim
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer RecurrenceCompletedPhase 3Galena Biopharma, Inc.NCT01479244Written as Leukine® (sargramostim, GM-CSF) and water for injection
Codes
What other systems call sargramostim · ClinicalTrials.gg INT003728
- MeSH (NLM) C081222sargramostimConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5TAA004E22SARGRAMOSTIMConfirmed FDA, NLM, Wikidata
- RxNorm 69634Confirmed FDA, Wikidata
- Wikidata Q3950557sargramostimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1492SargramostimOne source FDA
- DrugBank DB00020One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C081222 | sargramostim | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5TAA004E22 | SARGRAMOSTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 69634 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3950557 | sargramostim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1492 | Sargramostim | One source FDA |
| DrugBank | DB00020 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.